肥胖抑制素及和肽素预警多囊卵巢综合征患者心血管病变的初步研究

Obestatin and copeptin in early warning of cardiovascular disease in patients with polycystic ovary syndrome

目的研究肥胖抑制素与和肽素在肥胖型与非肥胖型多囊卵巢综合征(PCOS)患者和健康女性体内的表达差异,分析两者与PCOS患者并发心血管疾病危险因素指标的相关性。方法研究对象分为肥胖组、非肥胖组和对照组,用生化分析仪分析各项生化指标,化学发光法检测C反应蛋白(CRP)含量,空腹胰岛素水平采用激素自动分析仪进行检测,酶联免疫法检测和肽素、肥胖抑制素和睾酮。超声检测研究对象的颈动脉内-中膜厚度(CIMT)。多毛症通过Ferriman-Gallwey评分标准诊断,测量每个研究对象的腰臀比(WHR)和体重指数(BMI)。SPSS 11.5分析和肽素、肥胖抑制素和其他各项指标之间的关系。结果收缩压、舒张压和CRP在非肥胖组均高于对照组(P<0.05),肥胖组均高于非肥胖组(P<0.05)。F-G评分分值和总睾酮量在非肥胖组中高于对照组(P<0.05)。而肥胖组显著高于非肥胖组(P<0.05)。肥胖抑制素在非肥胖组明显低于对照组,肥胖组低于非肥胖组(P<0.05)。和肽素在肥胖组显著高于非肥胖组(P=0.002)。通过相关性分析显示肥胖抑制素与心血管危险因素呈负相关。和肽素与心血管危险因素之间呈正相关。结论肥胖抑制素在PCOS患者中低表达,和肽素在PCOS患者中高表达,在肥胖患者中这种趋势尤为明显。肥胖抑制素与心血管危险因素呈负相关,和肽素与心血管危险因素呈正相关,其均有望成为预测PCOS患者早期心血管病变的标志物。

Objective To explore the difference in the expression levels of obestatin and copeptin between patients with polycystic ovary syndrome（PCOS） and healthy women, and analyze their relationships with the risk factors of cardiovascular diseases in PCOS patients. Methods The study subjects were divided into three groups： the obese group, non-obese group and control group. The biochemical indexes and fasting insulin level were tested with biochemical analyzer and hormone automatic analyzer respectively. And the level of C-reactive protein（CRP） was measured by chemiluminescence method. ELISA was applied to test the expression levels of obestatin, copeptin and testosterone. Ultrasonic testing was used to detect carotid intima-media thickness（CIMT）, and hirsutism was diagnosed according to the Ferriman-Gallwey（F-G） scoring. Blood pressure, waist-to-hip ratio（WHR） and body mass index（BMI） were all measured. Then, SPSS 11.5 software was used to analyze the relationships between obestatin,copeptin and other parameters. Results Blood pressure and CRP were higher in the non-obese group than in the control group, and higher in the obese group than in the non-obese group（P〈0.05）. The F-G score and testosterone in the non-obese group were higher than those in the control group, and they were higher in the obese group than in the non-obese group, the differences were all statistically significant（P〈0.05）. The obestatin in the control group was higher in people with PCOS, and it was much lower in the obese group than in the non-obese group（P〈0.05）.On the contrary, the level of copeptin was higher in the obese group than in the non-obese group（P〈0.05）.Obestatin was negatively correlated with the cardiovascular risk factors; whereas copeptin was positively correlated with the cardiovascular risk factors. Conclusions Obestatin expression level is low while copeptin expression level is high in PCOS patients, especially in obese PCOS patients. Obestatin is negatively related with the cardiovascular risk factors, and copeptin is positively related with the cardiovascular risk factors. They both have the potential to be the biomarkers of early cardiovascular diseases in PCOS patients.